Top

Published in:

Open Access 01-12-2023 | COVID-19 | Review

The prevention and treatment of COVID-19 in patients treated with hemodialysis

Authors: Binyu Zeng, Jia Zhou, Daizhuang Peng, Chengmei Dong, Qun Qin

Published in: European Journal of Medical Research | Issue 1/2023

Abstract

Patients treated with hemodialysis are often immunocompromised due to concomitant disease. As a result, this population is at high risk of infection and mortality from COVID-19. In addition to symptomatic treatment, a series of antiviral drugs targeting COVID-19 are now emerging. However, these antivirals are used mainly in mild or moderate patients with high-risk factors for progression to severe disease and are not available as pre- or post-exposure prophylaxis for COVID-19. There is a lack of clinical data on the use of anti-COVID-19 drugs, especially in patients treated with hemodialysis, therefore, vaccination remains the main measure to prevent SARS-CoV-2 infection in these patients. Here, we review the clinical features and prognosis of patients on hemodialysis infected with SARS-CoV-2, the main anti-COVID-19 drugs currently available for clinical use, and the safety and efficacy of anti-COVID-19 drugs or COVID-19 vaccination in patients treated with hemodialysis. This information will provide a reference for the treatment and vaccination of COVID-19 in patients treated with hemodialysis and maximize the health benefits of these patients during the outbreak.

Cao Y, Liu X, Xiong L, Cai K. Imaging and clinical features of patients with 2019 novel coronavirus SARS-CoV-2: a systematic review and meta-analysis. J Med Virol. 2020;92(9):1449–59. https://doi.org/10.1002/jmv.25822.CrossRefPubMedPubMedCentral

Zhang J-j, Dong X, Cao Y-y, Yuan Y-d, Yang Y-b, Yan Y-q, et al. Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China. Allergy. 2020;75(7):1730–41. https://doi.org/10.1111/all.14238.CrossRefPubMed

Guan W, Ni Z, Hu Y, Liang W, Ou C, He J, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;382(18):1708–20. https://doi.org/10.1056/NEJMoa2002032.CrossRefPubMed

Rodriguez-Morales AJ, Cardona-Ospina JA, Gutierrez-Ocampo E, Villamizar-Pena R, Holguin-Rivera Y, Pablo Escalera-Antezana J, et al. Clinical, laboratory and imaging features of COVID-19: a systematic review and meta-analysis. Travel Med Infect Dis. 2020. https://doi.org/10.1016/j.tmaid.2020.101623.CrossRefPubMedPubMedCentral

Johnson KD, Harris C, Cain JK, Hummer C, Goyal H, Perisetti A. Pulmonary and extra-pulmonary clinical manifestations of COVID-19. Front Med. 2020. https://doi.org/10.3389/fmed.2020.00526.CrossRef

Elrobaa IH, New KJ. COVID-19: pulmonary and extra pulmonary manifestations. Front Public Health. 2021. https://doi.org/10.3389/fpubh.2021.711616.CrossRefPubMedPubMedCentral

Descamps-Latscha B, Herbelin A. Long-term dialysis and cellular immunity: a critical survey. Kidney Int Suppl. 1993;41:S135–42.PubMed

Haase M, Lesny P, Anderson M, Cloherty G, Stec M, Haase-Fielitz A, et al. Humoral immunogenicity and tolerability of heterologous ChAd/BNT compared with homologous BNT/BNT and ChAd/ChAd SARS-CoV-2 vaccination in hemodialysis patients. J Nephrol. 2022;35(5):1467–78. https://doi.org/10.1007/s40620-022-01247-7.CrossRefPubMedPubMedCentral

Gonzalez-Perez M, Montes-Casado M, Conde P, Cervera I, Baranda J, Berges-Buxeda MJ, et al. Development of potent cellular and humoral immune responses in long-term hemodialysis patients after 1273-mRNA SARS-CoV-2 vaccination. Front Immunol. 2022. https://doi.org/10.3389/fimmu.2022.845882.CrossRefPubMedPubMedCentral

10.

Davidovic T, Schimpf J, Abbassi-Nik A, Stockinger R, Sprenger-Maehr H, Lhotta K, et al. Humoral and cellular immune response after a 3-dose heterologous SARS-CoV-2 vaccination using the mRNA-BNT162b2 and viral vector Ad26COVS1 vaccine in hemodialysis patients. Front Immunol. 2022. https://doi.org/10.3389/fimmu.2022.907615.CrossRefPubMedPubMedCentral

11.

Hakim RM, Breyer J, Ismail N, Schulman G. Effects of dose of dialysis on morbidity and mortality. Am J Kidney Dis. 1994;23(5):661–9. https://doi.org/10.1016/s0272-6386(12)70276-7.CrossRefPubMed

12.

Held PJ, Port FK, Wolfe RA, Stannard DC, Carroll CE, Daugirdas JT, et al. The dose of hemodialysis and patient mortality. Kidney Int. 1996;50(2):550–6. https://doi.org/10.1038/ki.1996.348.CrossRefPubMed

13.

Fernandez P, Nunez S, De Arteaga J, Chiurchiu C, Douthat W, De La Fuente J. Inadequate doses of hemodialysis. Predisposing factors, causes and prevention. Med-Buenos Aires. 2017;77(2):111–6.

14.

Daugirdas JT, Depner TA, Inrig J, Mehrotra R, Rocco MV, Suri RS, et al. KDOQI clinical practice guideline for hemodialysis adequacy: 2015 update. Am J Kidney Dis. 2015;66(5):884–930.CrossRef

15.

Basile C, Lomonte C, Combe C, Covic A, Kirmizis D, Liakopoulos V, et al. A call to optimize haemodialysis vascular access care in healthcare disrupted by COVID-19 pandemic. J Nephrol. 2021;34(2):365–8. https://doi.org/10.1007/s40620-021-01002-4.CrossRefPubMedPubMedCentral

16.

Jager KJ, Kramer A, Chesnaye NC, Couchoud C, Emilio Sanchez-Alvarez J, Garneata L, et al. Results from the ERA-EDTA registry indicate a high mortality due to COVID-19 in dialysis patients and kidney transplant recipients across Europe. Kidney Int. 2020;98(6):1540–8. https://doi.org/10.1016/j.kint.2020.09.006.CrossRefPubMedPubMedCentral

17.

Rombola G, Heidempergher M, Cornacchiari M, Baragetti I, Pieruzzi F. SARS-CoV-2 and hemodialysis: diffusion and mortality in patients and health care team. Reflections from the lombardy experience. J Nephrol. 2021;34(2):277–9. https://doi.org/10.1007/s40620-021-01003-3.CrossRefPubMedPubMedCentral

18.

Sahin B, Kose S, Eren G, Yoruk G. Clinical features, management, and outcome of hemodialysis patients with SARS-CoV-2. Ther Apher Dial. 2022;26(1):171–7. https://doi.org/10.1111/1744-9987.13696.CrossRefPubMed

19.

Li P, Guan Y, Zhou S, Wang E, Sun P, Fei G, et al. Mortality and risk factors for COVID-19 in hemodialysis patients: a systematic review and meta-analysis. Sci Prog. 2022. https://doi.org/10.1177/00368504221110858.CrossRefPubMedPubMedCentral

20.

Zeng X, Huang X, Xu L, Xiao J, Gu L, Wang Y, et al. Clinical outcomes of dialysis patients with COVID-19 in the initial phase of the COVID-19 outbreak in Wuhan, China. Int Urol Nephrol. 2021;53(2):353–7. https://doi.org/10.1007/s11255-020-02670-0.CrossRefPubMed

21.

Ozturk S, Turgutalp K, Arici M, Odabas AR, Altiparmak MR, Aydin Z, et al. Mortality analysis of COVID-19 infection in chronic kidney disease, haemodialysis and renal transplant patients compared with patients without kidney disease: a nationwide analysis from Turkey. Nephrol Dial Transplant. 2020;35(12):2083–95. https://doi.org/10.1093/ndt/gfaa271.CrossRefPubMed

22.

Neugarten J, Golestaneh L, Kolhe NV. Sex differences in acute kidney injury requiring dialysis. Bmc Nephrol. 2018. https://doi.org/10.1186/s12882-018-0937-y.CrossRefPubMedPubMedCentral

23.

Seliger SL, Davis C, Stehman-Breen C. Gender and the progression of renal disease. Curr Opin Nephrol Hypertens. 2001;10(2):219–25. https://doi.org/10.1097/00041552-200103000-00010.CrossRefPubMed

24.

Neugarten J, Golestaneh L. Gender and the prevalence and progression of renal disease. Adv Chronic Kidney Dis. 2013;20(5):390–5. https://doi.org/10.1053/j.ackd.2013.05.004.CrossRefPubMed

25.

Moxley G, Posthuma D, Carlson P, Estrada E, Han JF, Benson LL, et al. Sexual dimorphism in innate immunity. Arthr Rheum. 2002;46(1):250–8.CrossRef

26.

Zhou S, Xu J, Xue C, Yang B, Mao Z, Ong ACM. Coronavirus-associated kidney outcomes in COVID-19, SARS, and MERS: a meta-analysis and systematic review. Renal Fail. 2020;43(1):1–15. https://doi.org/10.1080/0886022x.2020.1847724.CrossRef

27.

Cheng Y, Wong R, Soo YOY, Wong WS, Lee CK, Ng MHL, et al. Use of convalescent plasma therapy in SARS patients in Hong Kong. Eur J Clin Microbiol Infect Dis. 2005;24(1):44–6. https://doi.org/10.1007/s10096-004-1271-9.CrossRefPubMed

28.

Hung IFN, To KKW, Lee C-K, Lee K-L, Chan K, Yan W-W, et al. Convalescent plasma treatment reduced mortality in patients with severe pandemic influenza A (H1N1) 2009 virus infection. Clin Infect Dis. 2011;52(4):447–56. https://doi.org/10.1093/cid/ciq106.CrossRef

29.

Zhou B, Zhong N, Guan Y. Treatment with convalescent plasma for influenza A (H5N1) infection. N Engl J Med. 2007;357(14):1450–1. https://doi.org/10.1056/NEJMc070359.CrossRef

30.

van Griensven J, Edwards T, de Lamballerie X, Semple MG, Gallian P, Baize S, et al. Evaluation of convalescent plasma for ebola virus disease in guinea. N Engl J Med. 2016;374(1):33–42. https://doi.org/10.1056/NEJMoa1511812.CrossRefPubMedPubMedCentral

31.

Libster R, Marc GP, Wappner D, Coviello S, Bianchi A, Braem V, et al. Early high-titer plasma therapy to prevent severe Covid-19 in older adults. N Engl J Med. 2021;384(7):610–8. https://doi.org/10.1056/NEJMoa2033700.CrossRefPubMed

32.

Korley FK, Durkalski-Mauldin V, Yeatts SD, Schulman K, Davenport RD, Dumont LJ, et al. Early convalescent plasma for high-risk outpatients with Covid-19. N Engl J Med. 2021;385(21):1951–60. https://doi.org/10.1056/NEJMoa2103784.CrossRefPubMed

33.

Horby PW, Landray MJ, Grp RC. Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial. Lancet. 2021;397(10289):2049–59. https://doi.org/10.1016/s0140-6736(21)00897-7.CrossRef

34.

Zeng Q-L, Yu Z-J, Gou J-J, Li G-M, Ma S-H, Zhang G-F, et al. Effect of convalescent plasma therapy on viral shedding and survival in patients with coronavirus disease 2019. J Infect Dis. 2020;222(1):38–43. https://doi.org/10.1093/infdis/jiaa228.CrossRefPubMed

35.

Ortigoza MB, Yoon H, Goldfeld KS, Troxel AB, Daily JP, Wu Y, et al. Efficacy and safety of COVID-19 convalescent plasma in hospitalized patients a randomized clinical trial. Jama Intern Med. 2022;182(2):115–26. https://doi.org/10.1001/jamainternmed.2021.6850.CrossRefPubMed

36.

Begin P, Callum J, Jamula E, Cook R, Heddle NM, Tinmouth A, et al. Convalescent plasma for hospitalized patients with COVID-19: an open-label, randomized controlled trial. Nat Med. 2021;27(11):2012. https://doi.org/10.1038/s41591-021-01488-2.CrossRefPubMedPubMedCentral

37.

Perez EE, Orange JS, Bonilla F, Chinen J, Chinn IK, Dorsey M, et al. Update on the use of immunoglobulin in human disease: a review of evidence. J Allergy Clin Immunol. 2017;139(3):S1–46. https://doi.org/10.1016/j.jaci.2016.09.023.CrossRefPubMed

38.

Gharebaghi N, Nejadrahim R, Mousavi SJ, Sadat-Ebrahimi S-R, Hajizadeh R. The use of intravenous immunoglobulin gamma for the treatment of severe coronavirus disease 2019: a randomized placebo-controlled double-blind clinical trial. Bmc Infect Dis. 2020. https://doi.org/10.1186/s12879-020-05507-4.CrossRefPubMedCentral

39.

Shao Z, Feng Y, Zhong L, Xie Q, Lei M, Liu Z, et al. Clinical efficacy of intravenous immunoglobulin therapy in critical ill patients with COVID-19: a multicenter retrospective cohort study. Clin Trans Immunol. 2020. https://doi.org/10.1002/cti2.1192.CrossRef

40.

Xie Y, Cao S, Dong H, Li Q, Chen E, Zhang W, et al. Effect of regular intravenous immunoglobulin therapy on prognosis of severe pneumonia in patients with COVID-19. J Infect. 2020;81(2):340–3. https://doi.org/10.1016/j.jinf.2020.03.044.CrossRef

41.

Marcec R, Dodig VM, Radanovic I, Likic R. Intravenous immunoglobulin (IVIg) therapy in hospitalised adult COVID-19 patients: a systematic review and meta-analysis. Rev Med Virol. 2022. https://doi.org/10.1002/rmv.2397.CrossRefPubMedPubMedCentral

42.

Mazeraud A, Jamme M, Mancusi RL, Latroche C, Megarbane B, Siami S, et al. Intravenous immunoglobulins in patients with COVID-19-associated moderate-to-severe acute respiratory distress syndrome (ICAR): multicentre, double-blind, placebo- controlled, phase atrial. Lancet Respir Med. 2022;10(2):158–66. https://doi.org/10.1016/s2213-2600(21)00440-9.CrossRefPubMed

43.

Raman RS, Barge VB, Kumar DA, Dandu H, Kartha RR, Bafna V, et al. A phase II safety and efficacy study on prognosis of moderate pneumonia in coronavirus disease 2019 patients with regular intravenous immunoglobulin therapy. J Infect Dis. 2021;223(9):1538–43. https://doi.org/10.1093/infdis/jiab098.CrossRefPubMed

44.

Hwang YC, Lu RM, Su SC, Chiang PY, Ko SH, Ke FY, et al. Monoclonal antibodies for COVID-19 therapy and SARS-CoV-2 detection. J Biomed Sci. 2022;29(1):1. https://doi.org/10.1186/s12929-021-00784-w.CrossRefPubMedPubMedCentral

45.

Li D, Sempowski GD, Saunders KO, Acharya P, Haynes BF. SARS-CoV-2 neutralizing antibodies for COVID-19 prevention and treatment. Annu Rev Med. 2022;73:1–16. https://doi.org/10.1146/annurev-med-042420-113838.CrossRefPubMed

46.

Weinreich DM, Sivapalasingam S, Norton T, Ali S, Gao H, Bhore R, et al. REGEN-COV antibody combination and outcomes in outpatients with Covid-19. N Engl J Med. 2021. https://doi.org/10.1056/NEJMoa2108163.CrossRefPubMedPubMedCentral

47.

Dougan M, Nirula A, Azizad M, Mocherla B, Gottlieb RL, Chen P, et al. Bamlanivimab plus etesevimab in mild or moderate Covid-19. N Engl J Med. 2021;385(15):1382–92. https://doi.org/10.1056/NEJMoa2102685.CrossRefPubMed

48.

Levin MJ, Ustianowski A, De Wit S, Launay O, Avila M, Templeton A, et al. Intramuscular AZD7442 (Tixagevimab-Cilgavimab) for prevention of Covid-19. N Engl J Med. 2022;386(23):2188–200. https://doi.org/10.1056/NEJMoa2116620.CrossRefPubMed

49.

Owen DR, Allerton CMN, Anderson AS, Aschenbrenner L, Avery M, Berritt S, et al. An oral SARS-CoV-2 M-pro inhibitor clinical candidate for the treatment of COVID-19. Science. 2021;374(6575):1586. https://doi.org/10.1126/science.abl4784.CrossRefPubMed

50.

Hammond J, Leister-Tebbe H, Gardner A, Abreu P, Bao W, Wisemandle W, et al. Oral nirmatrelvir for high-risk, nonhospitalized adults with Covid-19. N Engl J Med. 2022;386(15):1397–408. https://doi.org/10.1056/NEJMoa2118542.CrossRefPubMed

51.

Wong CKH, Au ICH, Lau KTK, Lau EHY, Cowling BJ, Leung GM. Real-world effectiveness of molnupiravir and nirmatrelvir plus ritonavir against mortality, hospitalisation, and in-hospital outcomes among community-dwelling, ambulatory patients with confirmed SARS-CoV-2 infection during the omicron wave in Hong Kong: an observational study. Lancet. 2022;400(10359):1213–22. https://doi.org/10.1016/S0140-6736(22)01586-0.CrossRefPubMedPubMedCentral

52.

Saravolatz LD, Depcinski S, Sharma M. Molnupiravir and nirmatrelvir-ritonavir: oral coronavirus disease 2019 antiviral drugs. Clin Infect Dis. 2023;76(1):165–71. https://doi.org/10.1093/cid/ciac180.CrossRefPubMed

53.

Kabinger F, Stiller C, Schmitzoval J, Dienemann C, Kokic G, Hillen HS, et al. Mechanism of molnupiravir-induced SARS-CoV-2 mutagenesis. Nat Struct Mol Biol. 2021;28(9):740. https://doi.org/10.1038/s41594-021-00651-0.CrossRefPubMedPubMedCentral

54.

Bernal AJ, da Silva MMG, Musungaie DB, Kovalchuk E, Gonzalez A, Delos Reyes V, et al. Molnupiravir for oral treatment of Covid-19 in nonhospitalized patients. N Engl J Med. 2022;386(6):509–20. https://doi.org/10.1056/NEJMoa2116044.CrossRef

55.

Spinner CD, Gottlieb RL, Criner GJ, Arribas Lopez JR, Cattelan AM, Soriano Viladomiu A, et al. Effect of remdesivir vs standard care on clinical status at 11 days in patients with moderate covid-19 a randomized clinical trial. Jama-J Am Med Assoc. 2020;324(11):1048–57. https://doi.org/10.1001/jama.2020.16349.CrossRef

56.

Qian H-j, Wang Y, Zhang M-q, Xie Y-c, Wu Q-q, Liang L-y, et al. Safety, tolerability, and pharmacokinetics of VV116, an oral nucleoside analog against SARS-CoV-2, in Chinese healthy subjects. Acta Pharmacol Sin. 2022;43(12):3130–8. https://doi.org/10.1038/s41401-022-00895-6.CrossRefPubMedPubMedCentral

57.

Shen Y, Ai J, Lin N, Zhang H, Li Y, Wang H, et al. An open, prospective cohort study of VV116 in Chinese participants infected with SARS-CoV-2 omicron variants. Emerg Microbes Infect. 2022;11(1):1518–23. https://doi.org/10.1080/22221751.2022.2078230.CrossRefPubMedPubMedCentral

58.

Cao Z, Gao W, Bao H, Feng H, Mei S, Chen P, et al. VV116 versus nirmatrelvir-ritonavir for oral treatment of Covid-19. N Engl J Med. 2023;388(5):406–17. https://doi.org/10.1056/NEJMoa2208822.CrossRefPubMed

59.

Sun L, Peng Y, Yu W, Zhang Y, Liang L, Song C, et al. Mechanistic insight into antiretroviral potency of 2 ’-deoxy-2 ’-beta-fluoro-4 ’-azidocytidine (FNC) with a long-lasting effect on HIV-1 prevention. J Med Chem. 2020;63(15):8554–66. https://doi.org/10.1021/acs.jmedchem.0c00940.CrossRefPubMed

60.

Ren Z, Luo H, Yu Z, Song J, Liang L, Wang L, et al. A randomized, open-label, controlled clinical trial of azvudine tablets in the treatment of mild and common COVID-19, a pilot study. Adv Sci. 2020. https://doi.org/10.1002/advs.202001435.CrossRef

61.

Yu B, Chang J. Azvudine (FNC): a promising clinical candidate for COVID-19 treatment. Sig Transduct Target Ther. 2020. https://doi.org/10.1038/s41392-020-00351-z.CrossRef

62.

Ala M, Ala M. Metformin for cardiovascular protection, inflammatory bowel disease, osteoporosis, periodontitis, polycystic ovarian syndrome, neurodegeneration, cancer, inflammation and senescence: what is next? Acs Pharmacol Transl Sci. 2021;4(6):1747–70. https://doi.org/10.1021/acsptsci.1c00167.CrossRefPubMedPubMedCentral

63.

Shoshan-Barmatz V, Anand U, Nahon-Crystal E, Di Carlo M, Shteinfer-Kuzmine A. Adverse effects of metformin from diabetes to COVID-19, cancer, neurodegenerative diseases, and aging: is VDAC1 a common target? Front Physiol. 2021. https://doi.org/10.3389/fphys.2021.730048.CrossRefPubMedPubMedCentral

64.

Bramante CT, Buse J, Tamaritz L, Palacio A, Cohen K, Vojta D, et al. Outpatient metformin use is associated with reduced severity of COVID-19 disease in adults with overweight or obesity. J Med Virol. 2021;93(7):4273–9. https://doi.org/10.1002/jmv.26873.CrossRefPubMedPubMedCentral

65.

Li Y, Yang X, Yan P, Sun T, Zeng Z, Li S. Metformin in patients with COVID-19: a systematic review and meta-analysis. Front Med. 2021. https://doi.org/10.3389/fmed.2021.704666.CrossRefPubMedPubMedCentral

66.

Luo P, Qiu L, Liu Y, Liu X-l, Zheng J-l, Xue H-y, et al. Metformin treatment was associated with decreased mortality in COVID-19 patients with diabetes in a retrospective analysis. Am J Trop Med Hyg. 2020;103(1):69–72. https://doi.org/10.4269/ajtmh.20-0375.CrossRefPubMedPubMedCentral

67.

Ibrahim S, Lowe JR, Bramante CT, Shah S, Klatt NR, Sherwood N, et al. Metformin and Covid-19: focused review of mechanisms and current literature suggesting benefit. Front Endocrinol. 2021. https://doi.org/10.3389/fendo.2021.587801.CrossRef

68.

Bramante CT, Huling JD, Tignanelli CJ, Buse JB, Liebovitz DM, Nicklas JM, et al. Randomized trial of metformin, ivermectin, and fluvoxamine for Covid-19. N Engl J Med. 2022;387(7):599–610. https://doi.org/10.1056/NEJMoa2201662.CrossRefPubMedPubMedCentral

69.

Bramante CT, Buse JB, Liebovitz DM, Nicklas JM, Puskarich MA, Cohen K, et al. Outpatient treatment of COVID-19 and incidence of post-COVID-19 condition over 10 months (COVID-OUT): a multicentre, randomised, quadruple-blind, parallel-group, phase 3 trial. Lancet Infect Dis. 2023. https://doi.org/10.1016/s1473-3099(23)00299-2.CrossRefPubMed

70.

Bailey CJ, Gwilt M. Diabetes, metformin and the clinical course of Covid-19: outcomes, mechanisms and suggestions on the therapeutic use of metformin. Front Pharmacol. 2022. https://doi.org/10.3389/fphar.2022.784459.CrossRefPubMedPubMedCentral

71.

Sun F, Lin Y, Wang X, Gao Y, Ye S. Paxlovid in patients who are immunocompromised and hospitalised with SARS-CoV-2 infection. Lancet Infect Dis. 2022;22(9):1279. https://doi.org/10.1016/s1473-3099(22)00430-3.CrossRefPubMedPubMedCentral

72.

Poznanski P, Augustyniak-Bartosik H, Magiera-Zak A, Skalec K, Jakuszko K, Mazanowska O, et al. Molnupiravir when used alone seems to be safe and effective as outpatient COVID-19 therapy for hemodialyzed patients and kidney transplant recipients. Viruses. 2022. https://doi.org/10.3390/v14102224.CrossRefPubMed

73.

Blanchi S, Torreggiani M, Chatrenet A, Fois A, Maze B, Njandjo L, et al. COVID-19 vaccine hesitancy in patients on dialysis in Italy and France. Kidney Int Rep. 2021;6(11):2763–74. https://doi.org/10.1016/j.ekir.2021.08.030.CrossRefPubMedPubMedCentral

74.

Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med. 2021;384(5):403–16. https://doi.org/10.1056/NEJMoa2035389.CrossRefPubMed

75.

Falsey AR, Sobieszczyk ME, Hirsch I, Sproule S, Robb ML, Corey L, et al. Phase 3 safety and efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 vaccine. N Engl J Med. 2021;385(25):2348–60. https://doi.org/10.1056/NEJMoa2105290.CrossRefPubMed

76.

Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2020;383(27):2603–15. https://doi.org/10.1056/NEJMoa2034577.CrossRefPubMed

77.

Frenck RW Jr, Klein NP, Kitchin N, Gurtman A, Absalon J, Lockhart S, et al. Safety, immunogenicity, and efficacy of the BNT162b2 Covid-19 vaccine in adolescents. N Engl J Med. 2021;385(3):239–50. https://doi.org/10.1056/NEJMoa2107456.CrossRefPubMed

78.

Greinacher A, Thiele T, Warkentin TE, Weisser K, Kyrle PA, Eichinger S. Thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination. N Engl J Med. 2021;384(22):2092–101. https://doi.org/10.1056/NEJMoa2104840.CrossRefPubMed

79.

Stumpf J, Klimova A, Mauer R, Steglich A, Gembardt F, Martin H, et al. Equivalent humoral and cellular immune response but different side effect rates following SARS-CoV-2 vaccination in peritoneal and haemodialysis patients using messenger RNA vaccines. Nephrol Dial Trans. 2022;37(4):796–8. https://doi.org/10.1093/ndt/gfab324.CrossRef

80.

Zitt E, Davidovic T, Schimpf J, Abbassi-Nik A, Mutschlechner B, Ulmer H, et al. The safety and immunogenicity of the mRNA-BNT162b2 SARS-CoV-2 vaccine in hemodialysis patients. Front Immunol. 2021. https://doi.org/10.3389/fimmu.2021.704773.CrossRefPubMedPubMedCentral

81.

Murt A, Altiparmak MR, Yadigar S, Yalin SF, Ozbey D, Yildiz Z, et al. Antibody responses to the SARS-CoV-2 vaccines in hemodialysis patients: is inactivated vaccine effective? Ther Apher Dial. 2022;26(4):769–74. https://doi.org/10.1111/1744-9987.13752.CrossRefPubMed

82.

Goupil R, Benlarbi M, Beaubien-Souligny W, Nadeau-Fredette A-C, Chatterjee D, Goyette G, et al. Short-term antibody response after 1 dose of BNT162b2 vaccine in patients receiving hemodialysis. Can Med Assoc J. 2021;193(22):E793–800. https://doi.org/10.1503/cmaj.210673.CrossRef

83.

Jahn M, Korth J, Dorsch O, Anastasiou OE, Sorge-Haedicke B, Tyczynski B, et al. Humoral response to SARS-CoV-2-vaccination with BNT162b2 (Pfizer-BioNTech) in patients on hemodialysis. Vaccines. 2021. https://doi.org/10.3390/vaccines9040360.CrossRefPubMedPubMedCentral

84.

Grupper A, Sharon N, Finn T, Cohen R, Israel M, Agbaria A, et al. Humoral response to the pfizer BNT162b2 vaccine in patients undergoing maintenance hemodialysis. Clin J Am Soc Nephrol. 2021;16(7):1037–42. https://doi.org/10.2215/cjn.03500321.CrossRefPubMedPubMedCentral

85.

Frantzen L, Cavaille G, Thibeaut S, El-Haik Y. Efficacy of the BNT162b2 mRNA Covid-19 vaccine in a hemodialysis cohort. Nephrol Dial Transplant. 2021. https://doi.org/10.1093/ndt/gfab165.CrossRefPubMed

86.

Chan L, Fuca N, Zeldis E, Campbell KN, Shaikh A. Antibody response to mRNA-1273 SARS-CoV-2 vaccine in hemodialysis patients with and without prior COVID-19. Clin J Am Soc Nephrol. 2021;16(8):1258–60. https://doi.org/10.2215/cjn.04080321.CrossRefPubMedPubMedCentral

87.

Anand S, Montez-Rath ME, Han J, Garcia P, Cadden L, Hunsader P, et al. Antibody response to COVID-19 vaccination in patients receiving dialysis. J Am Soc Nephrol. 2021;32(10):2435–8. https://doi.org/10.1681/asn.2021050611.CrossRefPubMedPubMedCentral

88.

Longlune N, Nogier MB, Miedouge M, Gabilan C, Cartou C, Seigneuric B, et al. High immunogenicity of a messenger RNA-based vaccine against SARS-CoV-2 in chronic dialysis patients. Nephrol Dial Transplant. 2021;36(9):1704–9. https://doi.org/10.1093/ndt/gfab193.CrossRefPubMed

89.

Anft M, Blazquez-Navarro A, Paniskaki K, Skrzypczyk S, Appel H, Pfab T, et al. SARS-CoV-2-reactive cellular and humoral immunity in hemodialysis population. Kidney Int. 2021;99(6):1489–90. https://doi.org/10.1016/j.kint.2021.03.032.CrossRefPubMedPubMedCentral

90.

Paran Y, Saiag E, Spitzer A, Angel Y, Yakubovsky M, Padova H, et al. Short-term safety of booster immunization with BNT162b2 mRNA COVID-19 vaccine in healthcare workers. Open Forum Infect Dis. 2022. https://doi.org/10.1093/ofid/ofab656.CrossRefPubMed

91.

Dheir H, Tocoglu A, Toptan H, Pinar M, Demirci T, Koroglu M, et al. Short and mid-term SARS-CoV-2 antibody response after inactivated COVID-19 vaccine in hemodialysis and kidney transplant patients. J Med Virol. 2022;94(7):3176–83. https://doi.org/10.1002/jmv.27714.CrossRefPubMedPubMedCentral

92.

Espi M, Charmetant X, Barba T, Koppe L, Pelletier C, Kalbacher E, et al. The ROMANOV study found impaired humoral and cellular immune responses to SARS-CoV-2 mRNA vaccine in virus-unexposed patients receiving maintenance hemodialysis. Kidney Int. 2021;100(4):928–36. https://doi.org/10.1016/j.kint.2021.07.005.CrossRefPubMedCentral

93.

Speer C, Goeth D, Benning L, Buylaert M, Schaier M, Grenz J, et al. Early humoral responses of hemodialysis patients after COVID-19 vaccination with BNT162b2. Clin J Am Soc Nephrol. 2021;16(7):1073–82. https://doi.org/10.2215/cjn.03700321.CrossRefPubMedPubMedCentral

94.

Rincon-Arevalo H, Choi M, Stefanski A-L, Halleck F, Weber U, Szelinski F, et al. Impaired humoral immunity to SARS-CoV-2 BNT162b2 vaccine in kidney transplant recipients and dialysis patients. Sci Immunol. 2021. https://doi.org/10.1126/sciimmunol.abj1031.CrossRefPubMed

95.

Espi M, Charmetant X, Barba T, Mathieu C, Pelletier C, Koppe L, et al. A prospective observational study for justification, safety, and efficacy of a third dose of mRNA vaccine in patients receiving maintenance hemodialysis. Kidney Int. 2022;101(2):390–402. https://doi.org/10.1016/j.kint.2021.10.040.CrossRefPubMed

96.

Melin J, Svensson MK, Albinsson B, Winqvist O, Pauksens K. A third dose SARS-CoV-2 BNT162b2 mRNA vaccine results in improved immune response in hemodialysis patients. Upsala J Med Sci. 2022. https://doi.org/10.4810/ujms.v127.8959.CrossRefPubMedCentral

97.

Liu X, Shaw RH, Stuart ASV, Greenland M, Aley PK, Andrews NJ, et al. Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial. Lancet. 2021;398(10303):856–69. https://doi.org/10.1016/s0140-6736(21)01694-9.CrossRefPubMedPubMedCentral

98.

Barros-Martins J, Hammerschmidt SI, Cossmann A, Odak I, Stankov MV, Ramos GM, et al. Immune responses against SARS-CoV-2 variants after heterologous and homologous ChAdOx1 nCoV-19/BNT162b2 vaccination. Nat Med. 2021;27(9):1525. https://doi.org/10.1038/s41591-021-01449-9.CrossRefPubMedPubMedCentral

99.

Hillus D, Schwarz T, Tober-Lau P, Vanshylla K, Hastor H, Thibeault C, et al. Safety, reactogenicity, and immunogenicity of homologous and heterologous prime-boost immunisation with ChAdOx1 nCoV-19 and BNT162b2: a prospective cohort study. Lancet Respir Med. 2021;9(11):1255–65. https://doi.org/10.1016/s2213-2600(21)00357-x.CrossRefPubMedPubMedCentral

100.

Raja N, Rajagopalan A, Arunachalam J, Prasath A, Durai R, Rajendran M. Humoral response to viral vector COVID-19 vaccine in hemodialysis patients. Kidney Res Clin Pract. 2022;41(3):342–50. https://doi.org/10.2387/j.krcp.21.184.CrossRefPubMedPubMedCentral

101.

Agur T, Zingerman B, Ben-Dor N, Alkeesh W, Steinmetz T, Rachamimov R, et al. Humoral response to the third dose of BNT162b2 COVID-19 vaccine among hemodialysis patients. Nephron. 2023;147(3–4):185–92. https://doi.org/10.1159/000525519.CrossRefPubMed

102.

Puspitasari M, Sattwika PD, Hidayat ARP, Wijaya W, Wardhani Y, Intansari US, et al. Immunogenicity and safety of COVID-19 BNT162b2 booster vaccine in end-stage kidney disease patients receiving haemodialysis in Yogyakarta, Indonesia: a cohort prospective study. Bmc Nephrol. 2023. https://doi.org/10.1186/s12882-023-03218-x.CrossRefPubMedPubMedCentral

Title: The prevention and treatment of COVID-19 in patients treated with hemodialysis
Authors: Binyu Zeng
Jia Zhou
Daizhuang Peng
Chengmei Dong
Qun Qin
Publication date: 01-12-2023
Publisher: BioMed Central
Keywords: COVID-19
COVID-19 Vaccination
SARS-CoV-2
Vaccination
Published in: European Journal of Medical Research / Issue 1/2023
Electronic ISSN: 2047-783X
DOI: https://doi.org/10.1186/s40001-023-01389-9

Keynote webinar | Spotlight on medication adherence

Springer Medicine

The prevention and treatment of COVID-19 in patients treated with hemodialysis

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2023

ECMO in adult patients with severe trauma: a systematic review and meta-analysis

Association between leptin and NAFLD: a two-sample Mendelian randomization study

A landscape on disorders following different COVID-19 vaccination: a systematic review of Iranian case reports

Construction of a prediction model for rebleeding in patients with acute upper gastrointestinal bleeding

Mitofusin2 expression is associated with podocyte injury in IgA nephropathy

Extracellular vesicles derived from endothelial cells modulate macrophage phenotype in vitro